Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

New England Journal of Medicine

Volumn 349, Issue 24, 2003, Pages 2304-2315

  Shafer, Robert W ^a   Smeaton, Laura M ^b   Robbins, Gregory K ^c,p   De Gruttola, Victor ^b   Snyder, Sally W ^d   D'Aquila, Richard T ^e   Johnson, Victoria A ^f   Morse, Gene D ^g   Nokta, Mostafa A ^h   Martinez, Ana I ⁱ   Gripshover, Barbara M ^j   Kaul, Pamposh ^k   Haubrich, Richard ^l   Swingle, Mary ^m   McCarty, S Debra ⁿ   Vella, Stefano ^o   Hirsch, Martin S ^c   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ GLAXOSMITHKLINE   (United States)

^o ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; INITIAL THERAPY; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS MUTATION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION; NELFINAVIR; OXAZINES; STAVUDINE; TIME FACTORS; TREATMENT FAILURE; ZIDOVUDINE;

EID: 0344149561     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030265     Document Type: Article

References (20)

1. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HI-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000;160:1123-32.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353:863-8.
3. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000;14:141-9.
4. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed November 12, 2003, at http://www.aidsinfo.nih.gov/guidelines/adult/archive/AA_071403.html.)
5. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
6. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2291-301.
7. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000;12:255-66.
8. Division of AIDS table for grading severity of adult adverse experiences. Rockville, Md.: National Institute of Allergy and Infectious Diseases, August 1992.
9. Proportional hazards model. In: Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984:97-110.
10. Dube MP, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005S, a substudy of ACTG 384. Antiviral Ther 2002;7:L18. abstract.
11. Brinkman K, Smeitink JA, Romijn JA, Keiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
12. Squires KE. An introduction to nucleoside and nucleotide analogues. Antiviral Ther 2001;6:Suppl 3:1-14.
13. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
14. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Ther 2002;7:185-93.
15. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
16. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008.
17. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis 1999;179:808-16.
18. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000;283:205-11.
19. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283:229-34.
20. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001;15:1701-6.